Drug-induced liver injury

Lack of substantial advances in pre-clinical testing for hepatotoxicity has meant that drug-induced liver injury (DILI) remains an important issue during both the drug development and post-marketing phases. A number of drug-related, genetic and non-genetic host factors influence the risk of DILI in any individual.

Demonstration of human leukocyte antigen genotype as a strong risk factor for the development of DILI from a range of drugs has highlighted the role of the adaptive immune system in its pathogenesis; there is accumulating evidence that drug metabolism genes also contribute to some forms of DILI. Early recognition and prompt withdrawal of the drug is essential in preventing serious hepatic failure and is the critical step in the management of adverse reactions.

Diagnosis of DILI relies upon index of suspicion, careful evaluation of a temporal relationship between the exposure to a particular drug and the specific clinical event, and exclusion of potential alternative diagnoses. A high negative predictive value of genetic tests can be used to rule out DILI caused by particular drugs and to correctly identify the agent underlying DILI in a patient exposed to two concomitant medications.


Adverse drug reactiondrug-induced liver injuryhepatotoxicityhuman leukocyte antigenMRCPpharmacogenetics


More Posts

Imaging the liver and biliary tract

A variety of modalities is available to image the liver and biliary tract, many offering complementary information; a combination of techniques is often required to

Histological assessment

Histopathological assessments play an important role in the diagnosis and management of patients with liver disease. For some conditions, liver biopsy is still routinely used

Maribavir for Preemptive Treatment

Maribavir is a benzimidazole riboside with activity against cytomegalovirus (CMV). The safety and efficacy of maribavir for preemptive treatment of CMV infection in transplant recipients

Corporate Headquarters
234 5th Ave
New York, NY 10001
Scientific Headquarters
The Platinum Building
St John’s Innovation Park
Cowley Rd, Milton, Cambridge CB4 0DS
United Kingdom

Dante Labs